Loading clinical trials...
Loading clinical trials...
Randomized, Multicenter, Double-Blind, Placebo-Controlled, Rising Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 557 in Subjects With Systemic Lupus Erythematosus
This is a multicenter, randomized, double-blind, placebo-controlled, sequential rising single-dose study in which approximately 56 subjects with SLE will be enrolled in 7 dosing cohorts
Age
18 - 70 years
Sex
ALL
Healthy Volunteers
No
Research Site
Anniston, Alabama, United States
Research Site
Phoenix, Arizona, United States
Research Site
Los Angeles, California, United States
Research Site
Los Angeles, California, United States
Research Site
Michigan City, Indiana, United States
Research Site
North Dartmouth, Massachusetts, United States
Research Site
Manhasset, New York, United States
Research Site
New York, New York, United States
Research Site
Rochester, New York, United States
Research Site
Duncansville, Pennsylvania, United States
Start Date
November 1, 2006
Primary Completion Date
September 1, 2011
Completion Date
November 1, 2011
Last Updated
March 30, 2015
57
ACTUAL participants
AMG 557
DRUG
Placebo
DRUG
Lead Sponsor
Amgen
NCT06647069
NCT07371468
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06333483